Tested new drug could fight covid-19 and cancer

The ability of the SARS-CoV-2 virus to mutate and adapt to infect and replicate more efficiently, as we saw in the success of the BQ.1 variant, led a group of scientists from the University of Southern California (USC) in Cleveland, USA to investigate. your clinic The role of the chaperone (human body protein) GRP78 in the spread of the covid-19 virus🇧🇷

GRP78 regulates protein folding, a process essential for the correct biological function of cellular proteins. The researchers knew that while healthy cells use a small fraction of chaperones to function well, those under stress need more GRP78 to maintain this function.

When the authors realized that GRP78 was “essential and essential” for the replication of SARS-CoV-2 in human lung cells, they used a messenger RNA tool to suppress protein production. To test your hypotheses, decided to test the HA15, Cancer cell drug that also inhibits the activity of GRP78.

Fighting Covid-19 and Cancer

The HA15 test was praised by principal investigator Amy S. See, a professor at USC: “Look, we found this: this drug was very effective in reducing the number and size of SARS-CoV-2 plaques produced in infected cellsin safe doses with no harmful effects on normal cells.”

Lee and colleagues used another GRP78 inhibitor after testing it in the bodies of mice genetically engineered to express HA15 like a human receptor with covid-19. – YUM70 – Suppresses mutant KRAS proteins, such as HA15, that promote the proliferation of cancer cells.

While there are still basic proof-of-principle studies, results suggest that this and other GRP78 inhibitors may be effective. in the treatment of various strains of covid-19also for some more deadly types of cancer.

ARTICLE 🇧🇷 tumor – DOI: 10.1016/j.neo.2022.100837.